| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/26/2011 | EP2277858A1 Amide compound |
| 01/26/2011 | EP2277857A2 New crystalline form V of agomelatine, method of preparing same and pharmaceutical compositions containing same |
| 01/26/2011 | EP2277850A1 1-amino-alkylcyclohexanes as 5-HT3 and neuronal nicotinic receptor antagonists |
| 01/26/2011 | EP2277848A1 Indene derivatives as pharmaceutical agents |
| 01/26/2011 | EP2277595A2 Compounds for immunopotentiation |
| 01/26/2011 | EP2277594A2 Lysis / resealing process and device for incorporating an active ingredient in erythrocytes |
| 01/26/2011 | EP2277570A2 Medical devices containing rapamycin analogs |
| 01/26/2011 | EP2277569A2 Medical devices containing rapamycin analogs |
| 01/26/2011 | EP2277568A2 Medical devices containing rapamycin analogs |
| 01/26/2011 | EP2277567A1 Medical devices containing rapamycin analogs |
| 01/26/2011 | EP2277566A2 Medical devices containing rapamycin analogs |
| 01/26/2011 | EP2277565A2 Medical devices containing rapamycin analogs |
| 01/26/2011 | EP2277561A1 Ultra high molecular weight polyethylene articles and methods of forming ultra high molecular weight polyethylene articles |
| 01/26/2011 | EP2277560A1 Ultra high molecular weight polyethylene articles and methods od forming ultra high molecular weight polyethylene articles |
| 01/26/2011 | EP2277552A1 Mnk kinase proteins and diabetes |
| 01/26/2011 | EP2277551A2 Cyclodextrin-based polymers for delivering the therapeutic agents covalently bound thereto |
| 01/26/2011 | EP2277549A2 Therapeutic polyanhydride compounds for drug delivery |
| 01/26/2011 | EP2277546A1 Stable ready to use injectable paracetamol formulation |
| 01/26/2011 | EP2277544A1 Biocompatible magnetic nano-clusters containing iron oxide respectively iron oxide - boron with primary use in magnetic drug targeting and boron neutron capture therapy |
| 01/26/2011 | EP2277531A1 Treatment of cns damage |
| 01/26/2011 | EP2277526A1 Pharmaceutical composition with tetrahydroisohumulone |
| 01/26/2011 | EP2277525A1 A method for preparing extractive containing sequoyitol from nephrolepis family and application |
| 01/26/2011 | EP2277523A1 Use of megestrol acetate for the treatment of obstructive pulmonary diseases |
| 01/26/2011 | EP2277522A2 Methods for increasing or decreasing bone density and identifying molecules |
| 01/26/2011 | EP2277521A1 Tamper-resitant oral opioid agonist formulations |
| 01/26/2011 | EP2277520A2 A pharmaceutical composition for angiotensin ii-mediated diseases |
| 01/26/2011 | EP2277519A2 Use of Angiotensin II type 1 receptor antagonists for the prevention of stroke, diabetes and/or congestive heart failure |
| 01/26/2011 | EP2277518A1 Use of silymarin and silybin in the treatment of neural injury |
| 01/26/2011 | EP2277517A1 Nateglinide tablet composition |
| 01/26/2011 | EP2277516A1 Retinyl derivatives for treating ophtalmic conditions |
| 01/26/2011 | EP2277515A1 Use of the combination of teriflunomide and interferon beta for treating multiple sclerosis |
| 01/26/2011 | EP2277514A1 A method for chemoprevention of prostate cancer |
| 01/26/2011 | EP2277513A2 Treatment of incontinence with 5htc2 agonists |
| 01/26/2011 | EP2277512A2 Pharmaceutical compositions and dosage forms of thalidomide |
| 01/26/2011 | EP2277511A1 Extended release pharmaceutical compositions of levetiracetam |
| 01/26/2011 | EP2277510A2 Controlled release preparation |
| 01/26/2011 | EP2277507A1 Method of producing a cationic liposomal preparation comprising a lipophilic compound |
| 01/26/2011 | EP2277506A1 Non-polar buccal spray of a sedative |
| 01/26/2011 | EP2277505A2 Mucoactive agents for treating a pulmonary disease |
| 01/26/2011 | EP2277504A1 Substituted tetracycline compounds for the treatment of malaria |
| 01/26/2011 | EP2277503A1 Effervescent compositions comprising bisphosphonates and methods related thereto |
| 01/26/2011 | EP2277394A1 Nutritional composition for the treatment of pressure ulcers |
| 01/26/2011 | EP2277124A2 Means for treating myosin-related diseases |
| 01/26/2011 | EP2276833A1 Modulation of the immune response |
| 01/26/2011 | EP2276774A2 Therapeutic substances that modulate genome methylation |
| 01/26/2011 | EP2276773A2 Compounds with glycidic structure active in the therapy of systemic and local inflammation |
| 01/26/2011 | EP2276771A1 Solid forms of an anti-hiv phosphoindole compound |
| 01/26/2011 | EP2276769A1 New peptidomimetic compounds |
| 01/26/2011 | EP2276768A2 Process for the preparation of optically enriched clopidogrel |
| 01/26/2011 | EP2276767A1 Benzopyran and benzoxepin pi3k inhibitor compounds and methods of use |
| 01/26/2011 | EP2276766A1 Tricyclic antibiotics |
| 01/26/2011 | EP2276765A1 Salinosporamide derivatives as proteasome inhibitors |
| 01/26/2011 | EP2276764A1 Compounds for the treatment of hepatitis c |
| 01/26/2011 | EP2276762A1 Process for the preparation of sterile doripenem |
| 01/26/2011 | EP2276761A1 Carboxamide compounds for the treatment of metabolic disorders |
| 01/26/2011 | EP2276760A1 Fused ring compounds and use thereof |
| 01/26/2011 | EP2276759A1 3-indazolyl-4-pyridylisothiazoles |
| 01/26/2011 | EP2276758A1 Crystal forms of 5- [3- (2, 5-dichloro-4, 6-dimethyl-1-oxy-pyridine-3-yl) [1,2,3] oxadiazol-5-yl]-3-nit robenzene-1, 2-diol |
| 01/26/2011 | EP2276757A2 Macrocyclic compounds and methods of treatment |
| 01/26/2011 | EP2276756A1 Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists |
| 01/26/2011 | EP2276750A2 Substituted pyrimidines and triazines and their use in cancer therapy |
| 01/26/2011 | EP2276748A1 Bicyclic nitrogen containing heterocyclic compounds for use as stearoyl coa desaturase inhibitors |
| 01/26/2011 | EP2276747A1 Sulfonamides as zap-70 inhibitors |
| 01/26/2011 | EP2276744A1 1-aryl-3-aminoalkoxy pyrazoles as sigma ligands enhancing analgesic effect of opioids and attenuating the dependency thereof |
| 01/26/2011 | EP2276742A1 Ivabradine hydrobromide |
| 01/26/2011 | EP2276741A1 Isoquinolinone derivatives as nk3 antagonists |
| 01/26/2011 | EP2276738A1 Ether benzylidene piperidine 5-membered aryl carboxamide compounds useful as faah inhibitors |
| 01/26/2011 | EP2276737A1 4- [3- (aryloxy) benzylidene]-3-methyl piperidine aryl carboxamide compounds useful as faah inhibitors |
| 01/26/2011 | EP2276736A1 4- [3- (aryloxy) benzyliden]-3-methyl piperidine 5-membered aryl carboxamide compounds useful as faah inhibitors |
| 01/26/2011 | EP2276735A1 Ether benzylidene piperidine aryl carboxamide compounds useful as faah inhibitors |
| 01/26/2011 | EP2276734A1 4-benzylidene-3-methylpiperidine aryl carboxamide compounds useful as faah inhibitors |
| 01/26/2011 | EP2276732A1 Novel estrogen receptor ligands |
| 01/26/2011 | EP2276731A1 2-sulfonylamino-4-heteroaryl butyramide antagonists of ccr10 |
| 01/26/2011 | EP2276729A2 Novel compounds derived from taurine, process of their preparation and pharmaceutical compositions containing these |
| 01/26/2011 | EP2276726A1 Compounds for lysosomal modulation and methods of use |
| 01/26/2011 | EP2276722A2 Polymorphic form of an aminoindan mesylate derivative |
| 01/26/2011 | EP2276541A1 Maintenance of platelet inhibition during antiplatelet therapy |
| 01/26/2011 | EP2276508A1 Delivery of lfa-1 antagonists to the gastrointestinal system |
| 01/26/2011 | EP2276497A1 Ophthalmic device, and method of use thereof, for increasing ocular boundary lubrication |
| 01/26/2011 | EP2276496A1 Therapeutic modulation of ocular surface lubrication |
| 01/26/2011 | EP2276495A1 Stimulation of an immune response by enantiomers of cationic lipids |
| 01/26/2011 | EP2276494A1 Stable aqueous compositions comprising bioactive creatine species |
| 01/26/2011 | EP2276493A1 Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17 |
| 01/26/2011 | EP2276492A2 Sustained release delivery of active agents to treat glaucoma and ocular hypertension |
| 01/26/2011 | EP2276491A1 New therapy of treatment of the irritable bowel syndrome. |
| 01/26/2011 | EP2276490A1 Novel (pyrroloquinoxalinyl) pyrazinecarbohydrazide-oxalic acid co-crystal for treatment of cancer and other diseases |
| 01/26/2011 | EP2276489A2 Pterin based therapies for inflammatory conditions |
| 01/26/2011 | EP2276488A1 5imidazoquinolines and pyrimidine derivatives as potent modulators of vegf-driven angiogenic processes |
| 01/26/2011 | EP2276487A1 Piperlongumine and piperlongumine analogs for use in the treatment of cancer |
| 01/26/2011 | EP2276486A2 Novel substituted imidazoquinolines |
| 01/26/2011 | EP2276485A1 Use of epothelone d in treating tau-associated diseases including alzheimer's disease |
| 01/26/2011 | EP2276484A1 An antimicrobial composition |
| 01/26/2011 | EP2276483A1 Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
| 01/26/2011 | EP2276482A2 Hsp90 inhibitors or modulators for treatment or prevention of substance-related disorders |
| 01/26/2011 | EP2276481A1 Use of benzo-fused heterocycle sulfamide derivatives for the treatment of anxiety |
| 01/26/2011 | EP2276480A2 Calycosin and analogs thereof for the treatment of estrogen receptor beta-mediated diseases |
| 01/26/2011 | EP2276479A2 Prodrugs of neuraminidase inhibitors |
| 01/26/2011 | EP2276478A1 Methods of administering prostratin and structural analogs thereof |
| 01/26/2011 | EP2276473A1 Carbidopa/lipodopa gastroretentive drug delivery |
| 01/26/2011 | EP2276470A2 Alpha adrenergic receptor agonists for treatment of pain and/or inflammation |